Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pegylated liposomal doxorubicin hydrochloride
Find trials that include:  Any drugs shown
Results 1-21 of 21 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8109-002, NCI-2011-00940, EC-FV-06, NCT01170650
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR100983, NCI-2013-01419, 2012-004808-34, ET743OVC3006, NCT01846611
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MM08-141, NCI-2012-00848, NCT01177683
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201102043, NCI-2011-00224, NCT01246063
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1011004095, 1103-09, NCT01485874
Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin Hydrochloride For Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17814, NCI-2014-02019, 14.07.0046, NCT02186834
Pegylated Liposomal Doxorubicin Hydrochloride and Bevacizumab in Treating Patients with Advanced Kaposi Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0130, NCI-2013-01450, 090130, NCT00902239, P09493, NCT00923936
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 to 80
Trial IDs: UCDCC#230, NCI-2014-00564, 322070-12, X05385, NCT01736943
BRCA1 Protein Expression in Patients With Metastatic Breast Cancer Receiving Pegylated Liposomal Doxorubicin Hydrochloride
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 1300000710, NCI-2013-02365, NCT01990352
Avatar-Directed Chemotherapy in Treating Patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1463, NCI-2014-02399, Mod14-002986-03, NCT02312245
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 05B5, NCI-2011-00325, NU-1838-001, NCT00316875
Pegylated Liposomal Doxorubicin Hydrochloride, Bevacizumab, and Temsirolimus in Treating Patients With Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 2008-0384, NCI-2012-01665, NCT00761644
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-01206, NCI-2012-03161, AECM-000248, 8475, 00-0248, NCT01145430
Romidepsin and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Stage IB-IVB Relapsed or Refractory T-cell Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 112516, NCI-2014-01722, CC#112516, RM-CTCL-PI-0012, UCSF CC# 112516, UCSF Protocol Number 112516, NCT01902225
Ibrutinib, Temozolomide, Etoposide, Pegylated Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Rituximab in Treating Patients with Primary Central Nervous System Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0157, NCI-2014-01754, 09-25-0099, 140157, 14-C-0157_9577, 9577, NCT02203526
Surgery and Chemotherapy with or without Chemotherapy after Surgery in Treating Patients with Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
Phase: No phase specified
Type: Tissue collection/Repository, Treatment
Age: 18 and older
Trial IDs: 12316, NCI-2013-01948, 108303, 116613, NCT01970722
Start Over